Advertisement

Topics

Clinical Trials About "Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy" RSS

09:57 EDT 24th September 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy" on BioPortfolio

We have published hundreds of Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy news stories on BioPortfolio along with dozens of Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy Clinical Trials and PubMed Articles about Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy Companies in our database. You can also find out about relevant Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy Drugs and Medications on this site too.

Showing "Redirected High Affinity Specific Autologous Cells Gene Therapy" Clinical Trials 1–25 of 36,000+

Extremely Relevant

Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy

This research study is being carried out to study a new way to possibly treat HIV. T‐cells are one of the white blood cells used by the body to fight HIV. CD8 T‐cells are a type of T‐cell used by the body to detect and kill cells which have been infected by foreign viruses or organisms,including the HIV virus. CD8 T‐cells must identify the HIV virus in order to kill it. Because HIV is constantly changing the way it looks to the CD8 T‐cells, some of the HIV virus escap...


NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains (referred to as "RNA CART19") in Hodgkin Lymphoma (HL) patients. Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks.


CD19-redirected Autologous Cells (CAR-CD19 T Cells)

This study is designed for determining the safety and relative engraftment levels of the redirected autologous T cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell leukemia and malignant lymphoma.

TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation

Hepatocellular carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver transplantation and are confirmed to have recurrent HCC. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population.

Lentiviral Gene Therapy for CGD

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

HCC recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 subjects with HBV-related Hepatocellular carcinoma after liver transplantation. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV/TCR redirected T cell in the target population.

NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC

TCR-T cell therapy experienced a breakthrough for treating tumors in recent years. Phase I / II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma conducted by the Rosenberg team at the National Cancer Institute showed that 61% Synovial cell sarcoma and 55% melanoma had therapeutic responses. Another report of a phase I / II clinical trial for multiple myeloma showed that 20 patients received high affinity anti-NY-ESO-1 and LAGE-1 specific TCR-T treatm...

Relevant

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

This is a single arm, open-label, one center, dose escalation clinical study to determine the safety and efficacy of infusion of autologous T cells expressing CD19-redirected Chimeric Antigen Receptor (CD19 CAR T) in adult patients with relapsed or refractory CD19 positive B-cell lymphoma.

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

The main purpose of this trial is to investigate the safety and tolerability of NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)in the first-line treatment failed advanced bone and soft tissue sarcoma. The secondary purpose of this trial is to investigate the efficacy of NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)in the first-line treatment failed advanced bone and soft tissue sarcoma.

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors

The main purpose of this trial is to investigate the safety and tolerability of TAEST16001(TCR Affinity Enhancing Specific T cell Therapy)in the multi-line treatment failed advanced solid tumors including bone and soft tissue sarcoma, melanoma, liver cancer, esophageal cancer, breast cancer, thyroid and ovarian cancer. The patients must meet the two criteria: human leukocyte antigens (HLA)-A*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemisty.

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19) in Hodgkin Lymphoma (HL) patients.

CD123 Redirected Autologous T Cells for AML

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

This is a phase I study which will test the safety of different doses of the patients own immune cells which have been changed to help recognize and destroy the cancer cells. The investigators want to find out what effects, good and/or bad, it has on the body and on the prostate cancer. The immune cells (T cells) used in this study will be the patients own immune cells. They will be removed from the patients blood, changed in the laboratory, and then put back into their body. T...

Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer

This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated. Subjects will be treated with i.v. administration of 1 to 3e8 per meter squared RNA CAR T cells three times weekly (M-W-F) for three weeks.

Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer

The study "Phase I trial of Adoptive T cell Therapy with Activated P53 specific T cells for Treatment of Advanced Colorectal Cancer" is an open label, single arm trial. Most patients with colorectal carcinoma (CRC) accumulate high numbers of endogenous tumor antigen specific cytotoxic and helper memory T cells in their blood. Upon appropriate reactivation, tumor antigen specific T cells can recognize and eliminate autologous tumor cells. This can be achieved ex vivo by their s...

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells. Vaccines made from a gene modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy may kill more tumor cells. PURPOSE: This phase II...

CD22 Redirected Autologous T Cells for ALL

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Gene Therapy for WAS

This is a phase I/II study to evaluate the safety and efficacy of Hematopoietic Stem Cell genetherapy for the Wiskott-Aldrich Syndrome.

Gene Therapy of Beta Thalathemia Using a Self-inactivating Lentiviral Vector

This is a Phase I/II clinical trial of gene transfer for treating Beta-thalassemia using a self-inactivating lentiviral vector to functionally correct the defective gene(s). The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2). The treatments that the investigators are studying try to improve the immune system by changing some of your T cells so they can find and destroy HIV infected cells (HIV is usually able to hide from your T cells). In this study, the investigators are also trying to find out if giving you mo...

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.

Gene Therapy for Fanconi Anemia

This pilot trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with FA.

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

This is a phase 2 study to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans. In this phase 2 study, the experimental products are given initially to a group of 8 people, and if safe and found to have a significant antitumor activity, it will be given to up to 14 other people, for a total of 22 people in this study. The study investigators' main aim is to obtain sufficient information about the effects of ...

Gene Therapy for SCID-X1 Using a Self Lentiviral Vector

This is a Phase I/II clinical trial of gene therapy for X-linked severe combined immunodeficiency (SCID-X1) using a self lentiviral vector to replace the defective genes with good genes. The primary objectives are to evaluate the safety and efficacy of the ex vivo gene therapy clinical protocol.


More From BioPortfolio on "Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy"

Advertisement
Quick Search
Advertisement
Advertisement